Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bristol gets option to acquire Promedior for up to $1.25bn; withdrawn

Executive Summary

Bristol-Myers Squibb Co. received the exclusive right to buy Promedior Inc., a private rare fibrotic disease drug developer. BMS pays $150mm up front (covering the right to acquire and for Phase II-related support services); an option exercise fee; and clinical and regulatory earn-outs. In all, the deal could be worth up to $1.25bn.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies